This portable instrument treats with NovaVision’s VRT therapy technology to provide improvement in the range or sensitivity of the patient’s field of vision. Omnica developed this home use transforming device to accommodate a full range of patient percentiles and provide a convenient way to go mobile with your therapy. NovaVision’s VRT uses repetitive light stimulation to activate impaired visual functions in areas of partial injury (“transition zones”), strengthening the residual vision and neuronal networks. The concept of repetitive stimulation has proven effective in the recovery of other functions such as movements of lower limbs after stroke.
R&D requires low-volume, functional prototypes and fixtures. This project’s goal was to detect and quantify particulate passing through the carotid artery during coronary surgery. The results were rather stunning and enabled our client to better understand vital program issues.
SSO2 THERAPY FOR AMI
Current standard of care for the most severe heart attacks involves mechanically opening the blocked artery using percutaneous coronary intervention (PCI), otherwise known as angioplasty and stenting. While PCI has reduced early mortality post-heart attack over the past 25 years, significant myocardial tissue (heart muscle) death and sizable scarring may be present even after the left anterior descending (LAD) artery has been stented. This myocardial damage is linked to increased risk of heart failure and long-term mortality2.
SSO2Therapy is a novel treatment that complements PCI and is designed to minimize myocardial damage caused by acute myocardial infarction in qualifying patients suffering a LAD ST-elevation myocardial infarction (STEMI) event who are treated with primary PCI within 6 hours of symptom onset. SSO2 Therapy delivers superoxygenated arterial blood directly to at-risk myocardial tissue and is performed in the cardiac catheterization laboratory immediately after PCI is completed.
Day after day, analytical testing laboratories face considerable challenges due to backlogs of time-critical samples, rising per-sample costs, availability of skilled laboratory technicians, and chromatography maintenance and downtime. The Thermo Scientific™ VeriSpray™ PaperSpray ion source uniquely addresses these concerns. Combine the VeriSpray ion source with next-generation Thermo Scientific™ mass spectrometers to reduce time to results and cost per test with automated, high-throughput, direct mass spectrometry (MS)-based sample analysis. The VeriSpray ion source allows use of “dilute and shoot” methods to minimize solvent consumption and time-consuming sample preparation steps like derivatization, while avoiding needs for expert operators and instrument downtime. For laboratories currently performing LC or GC methods, or for those that want to add the robust sensitivity and selectivity of MS-based tests, the VeriSpray ion source provides an ideal alternative to the complexity of chromatography-based solutions.
Omnica’s initial engagement was for packaging the client’s blood pump controller with a design that passed a number of challenging requirements. In parallel, we designed a rechargeable battery pack system. The project included fully functional prototypes, production part design and documentation.
Our involvement evolved to include pump design evaluation, new feature development, testing and troubleshooting consultation programs.
When we first met the Inogen group, they were already familiar with our work on the HELiOs Personal Oxygen System the conserver we had developed for Nellcor Puritan-Bennett three years before. Inogen wanted us to duplicate this success for them in the oxygen concentrator market. An oxygen concentrator is a device that cleans nitrogen from ambient air and supplies a continuous flow of pure (about 95%) oxygen to the user by way of an air tube called a nasal cannula.
The conserver market has boomed, largely due to the success of the HELiOs™ system.
The main issue with these types of devices is that they require refilling from a large liquid oxygen tank every few hours. Concentrators don’t need refilling, but for other reasons, business has not fared so well. Inogen’s idea was to re-think the technology and re-define the category.
The concentrator market had been in decline for many years. For COPD patients on the go, concentrators added a degree of mobility, but the units were big and noisy, and needed to be connected to a wall socket. It was also difficult to sell a product that was industrial looking and heavy to lug about. Inogen planned to develop a lightweight, efficient, and quiet portable oxygen concentrator that could run on batteries.
Start-up company needed help developing a funtional prototype.
The start-up company presented us with a very preliminary prototype that worked, but had only limited functionality. They had already completed a portion of the initial development and had identified some proprietary components they wanted to incorporate into the final design. Their plan was to use off-the-shelf parts, hire us for the I.D., and make a real product out of what they had. But like most of the devices we develop, almost all of the components eventually had to be custom designed.
Over the period of about a year, their group completed the electronics and software development. Concurrently, Omnica performed the industrial design, mechanical layout, the internal and external packaging, battery case, chargers, carts, the satellite conserver valve, the manifold design, and the extrusion and chassis assembly. Omnica worked with other vendors to successfully miniaturize the pneumatics and valving for use in the lightweight design. We even built the production test equipment, the manifold leak testers, and later approved the first articles.
We fabricated 18 pre-production prototypes of the Inogen One OxygenConcentrator System™.
Our client used them to introduce the product in a trade show. Reaction to the new device was overwhelming, and on that basis, the company made projections of how many units to manufacture as a first run of the product. Six months later, when the concentrator actually became available to the market, they had to dramatically revamp production forecasts to keep up with rapidly rising demand.
The concentrator runs on batteries and is approved for use on most airlines.
The Inogen One Oxygen Concentrator System fulfilled the promise of independence for highly active home oxygen patients. It weighs 10 pounds, and runs for 2 to 3 hours on rechargeable batteries (indefinitely on A/C). It is very quiet and features a breath detection system four times as efficient as other concentrators. The Inogen One is the only oxygen concentrator which meets 100% of FAA requirements for use upon aircraft. It has won three awards including the prestigious MDEA design excellence award.